Logo

Paired Ends: Gerhard Burbach

Jan 15, 2013
Premium

Fluidigm has appointed Gerhard Burbach to its board of directors. Burbach currently serves as CEO and director of Thoratec. Previously, he served as president and CEO of Digirad and has been a member of Digirad's board of directors since 2004. He holds a BS in industrial engineering from Stanford University and an MBA from Harvard Business School.

Filed under

Clinical Sequencing
Sequencing
Next-Generation Sequencing
Fluidigm
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.